Over the last decade, advances in genetics, neuroimaging and EEG have enabled the
aetiology of epilepsy to be identified earlier in the disease course than ever before. At the …

Summary Since 1989, 18 second-generation antiseizure medications have reached the
market, resulting in a greatly increased range of treatment options for patients and …

Epilepsies of early childhood are frequently resistant to therapy and often associated with
cognitive and behavioural comorbidity. Aetiology focused precision medicine, notably gene …

Tuberous sclerosis complex is a rare genetic disease associated with mutations in the TSC1
or TSC2 genes, which cause overactivation of the mTOR complex. In the past 5 years …

Children with infantile spasms are likely to have a poor outcome. Outcome measures for
infantile spasms include primary response to treatment, relapse of spasms, neurological …

Impairments in cognition are common in epilepsy and may be caused or exacerbated by
antiseizure medications (ASMs). Positive effects on cognition may also be seen with some …

Introduction: Nonsulfated neurosteroids can provide phasic and tonic inhibition through
activation of synaptic and extra-synaptic γ-aminobutyric acid (GABA) A receptors, exhibiting …

CDKL5 Deficiency Disorder (CDD) is a rare, X-linked dominant condition that causes a
developmental and epileptic encephalopathy (DEE). The incidence is between~ 1: 40,000 …

Objective To determine the underlying etiologies in a contemporary cohort of infants with
infantile spasms and to examine response to treatment. Methods Identification of the …

Abstract Objective Antiseizure medications (ASMs) remain the mainstay of epilepsy
treatment. These ASMs have mainly been tested in trials in adults with epilepsy, which …